← Back to Search

Other

GSK1070806 for Atopic Dermatitis

Phase 1
Waitlist Available
Research Sponsored by GlaxoSmithKline
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (day 1) and at week 12

Summary

This trial is testing a new medication called GSK1070806 to see if it can help people with moderate to severe atopic dermatitis by reducing inflammation and itching.

Eligible Conditions
  • Atopic Dermatitis
  • Eczema

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (day 1) and at week 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (day 1) and at week 12 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Percent Change From Baseline (PCFB) in Eczema Area and Severity Index (EASI) Score at Week 12 in Group 1
Secondary study objectives
Change From Baseline in EASI Score at Week 12 in Group 1
Number of Participants Achieving EASI-50, ≥ 50% Reduction in EASI Score at Week 12 in Group 1
Number of Participants Achieving EASI-75, ≥ 75% Reduction in EASI Score at Week 12 in Group 1
+10 more

Side effects data

From 2023 Phase 1 trial • 34 Patients • NCT04975438
9%
COVID-19
4%
Dermal cyst
4%
Face injury
4%
Back pain
4%
Gastroenteritis
4%
Urticaria
4%
White blood cell disorder
4%
Headache
4%
Neutrophil count abnormal
4%
Suspected COVID-19
4%
Hyponatraemia
4%
Dermatitis
4%
Diarrhoea
4%
Hyperhidrosis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
GSK1070806

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: Group 2: Dupilumab-IR with GSK1070806Experimental Treatment1 Intervention
Participants received a single dose of 2 mg/kg GSK1070806 as intravenous infusion on Day 1.
Group II: Group 1: GSK1070806Experimental Treatment1 Intervention
Participants received a single dose of 2 mg/kg GSK1070806 as intravenous infusion on Day 1.
Group III: Group 2: Dupilumab IR with PlaceboPlacebo Group1 Intervention
Participants received Placebo as intravenous infusion on Day 1.
Group IV: Group 1: PlaceboPlacebo Group1 Intervention
Participants received Placebo as intravenous infusion on Day 1.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
GSK1070806
2022
Completed Phase 2
~200

Find a Location

Who is running the clinical trial?

GlaxoSmithKlineLead Sponsor
4,802 Previous Clinical Trials
8,377,968 Total Patients Enrolled
GSK Clinical TrialsStudy DirectorGlaxoSmithKline
3,604 Previous Clinical Trials
6,144,674 Total Patients Enrolled
~9 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top